Europe 3D Printed Drugs Market

Europe 3D Printed Drugs Market Size (2022 To 2027)

The 3D printed drugs market in Europe is expected to grow from USD 134.3 million in 2022 to USD 188.5 million by 2027, rising at a CAGR of 7.01% from 2022 to 2027.

The growing adoption of personalized drugs across the European region primarily drives the Europe 3D printed drugs market growth. Personalized drugs are a valued application of 3D printing. In the Pharmacy sector, 3D printing drugs help reduce the risk of errors in the supply chain and reduce the cost of drug manufacturing. It also provides safe, new, and cost-effective drugs in less time. In addition, personalized drugs provide patients with fast relief from the illness.

The increasing prevalence of dysphagia in the European region is further fuelling the growth of the European 3D printed drugs market. Nearly 25% to 45% of the pediatric population suffer from dysphagia. However, due to the heavy dosage and effects of the drug, many people are not interested in taking the pills. In some situations, the pills get stuck in the throat, leading to severe pain or a critical situation. Considering all these issues, 3D-printed drugs are manufactured in small quantities with the required dosage for any age group and dissolve faster than traditional medicine. Therefore, due to the advantages of 3D-printed drugs, many people are adopting the drugs, which helps the demand for market growth.

Furthermore, the growing adoption of 3D-printed drugs, the presence of key market players, and the growing investments by the governments of European countries are anticipated to support regional market growth. In addition, the growing usage of advanced technologies in the software used to produce 3D-printed drugs favors the market growth in Europe.

The misusing 3D printing machines to manufacture illegal drugs is expected to hamper the regional market growth. In addition, the need for government approvals for 3D-printed drugs hinders the market growth. Side effects of these drugs, lack of awareness about the 3D printed drugs, and lack of proper infrastructure in the laboratories are the other factors that impede the market growth.

This research report on the European 3D printed drugs market has been segmented & sub-segmented into the following categories:

By Scenario:

• Low Growth Scenario
• Moderate Growth Scenario
• Rapid Growth Scenario

By End User:

• Hospitals
• Clinics
• Research Laboratories
• Others

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region occupied the second-largest worldwide market share in 2021. During the forecast period, the European market is predicted to showcase a healthy CAGR owing to the increasing adoption of advanced infrastructure in the healthcare and pharmaceutical sector. For instance, during the Covid-19 pandemic, many hospitals in Europe preferred to have virus filtration systems to reduce the spread of the coronavirus among patients, healthcare providers, and healthcare workers.

The UK market is estimated to capture the leading share of the European market during the forecast period owing to the growing number of product approvals. In addition, the OVER company launched an advanced sustainable filter-free air purification system named CrossField in 2021, which helps combat airborne viruses and bacteria, including COVID-19.

The German market is expected to showcase a notable CAGR in the coming years. Increasing virus filter training services centres in Germany is primarily driving the market growth in Germany. In addition, due to increasing technological advancements, most people need to know about the working process for better results in virus filtration devices. Furthermore, increasing manufacturing units in the region fuels the market growth in Germany.

KEY MARKET PLAYERS:

Osmotica Pharmaceuticals, GSK Group of Companies, Formac Pharmaceuticals, Extend Biosciences, Affinity Therapeutics, FabRx Ltd., Hewlett Packard Caribe, Merck & Co., Inc., Cycle Pharmaceuticals, AstraZeneca and Aprecia are some of the prominent players in the global 3D printed drugs market.